High-throughput screening identifies small molecule inhibitors of thioesterase superfamily member 1: Implications for the management of non-alcoholic fatty liver disease

Autor: Krumm, Christopher S., Landzberg, Renée S., Ramos-Espiritu, Lavoisier, Adura, Carolina, Liu, Xu, Acuna, Mariana, Xie, Yang, Xu, Xu, Tillman, Matthew C., Li, Yingxia, Glickman, J. Fraser, Ortlund, Eric A., Ginn, John D., Cohen, David E.

Publikováno v: In Molecular Metabolism December 2023 78

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.

Autor: Pulaski H; PathAI, Inc., Boston, MA, USA., Harrison SA; Pinnacle Clinical Research, San Antonio, TX, USA., Mehta SS; PathAI, Inc., Boston, MA, USA.; AbbVie, Inc., Irvine, CA, USA., Sanyal AJ; Virginia Commonwealth University, Richmond, VA, USA., Vitali MC; PathAI, Inc., Boston, MA, USA.; Whoop Inc., Boston, MA, USA., Manigat LC; PathAI, Inc., Boston, MA, USA., Hou H; PathAI, Inc., Boston, MA, USA., Madasu Christudoss SP; PathAI, Inc., Boston, MA, USA.; Invicro, Needham, MA, USA., Hoffman SM; PathAI, Inc., Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Stanford-Moore A; PathAI, Inc., Boston, MA, USA., Egger R; PathAI, Inc., Boston, MA, USA., Glickman J; PathAI, Inc., Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Resnick M; PathAI, Inc., Boston, MA, USA.; Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Brown University, Providence, RI, USA., Patel N; PathAI, Inc., Boston, MA, USA., Taylor CE; PathAI, Inc., Boston, MA, USA., Myers RP; OrsoBio, Inc., Palo Alto, CA, USA., Chung C; Inipharm, Inc., Bellevue, WA, USA., Patterson SD; Gilead Sciences, Inc., Foster City, CA, USA., Sejling AS; Novo Nordisk, Bagsvaerd, Denmark., Minnich A; Bristol Myers Squibb, Princeton, NJ, USA., Baxi V; Bristol Myers Squibb, Princeton, NJ, USA., Subramaniam GM; OrsoBio, Inc., Palo Alto, CA, USA., Anstee QM; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Loomba R; UCSD School of Medicine, San Diego, CA, USA., Ratziu V; Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assisstance Publique Hôpitaux de Paris, INSERM UMRS, Paris, France., Montalto MC; PathAI, Inc., Boston, MA, USA.; Amgen, Thousand Oaks, CA, USA., Anderson NP; PathAI, Inc., Boston, MA, USA., Beck AH; PathAI, Inc., Boston, MA, USA., Wack KE; PathAI, Inc., Boston, MA, USA. katy.wack@pathai.com.

Publikováno v: Nature medicine [Nat Med] 2024 Nov 04. Date of Electronic Publication: 2024 Nov 04.

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.

Autor: Iyer JS; PathAI, Boston, MA, USA.; Absci, Vancouver, WA, USA., Juyal D; PathAI, Boston, MA, USA., Le Q; PathAI, Boston, MA, USA., Shanis Z; PathAI, Boston, MA, USA., Pokkalla H; PathAI, Boston, MA, USA., Pouryahya M; PathAI, Boston, MA, USA.; AstraZeneca, Gaithersburg, MD, USA., Pedawi A; PathAI, Boston, MA, USA.; Atomwise, San Francisco, CA, USA., Stanford-Moore SA; PathAI, Boston, MA, USA., Biddle-Snead C; PathAI, Boston, MA, USA., Carrasco-Zevallos O; PathAI, Boston, MA, USA.; Johnson & Johnson, New Brunswick, NJ, USA., Lin M; PathAI, Boston, MA, USA.; Supernus Pharmaceuticals, Rockville, MD, USA., Egger R; PathAI, Boston, MA, USA., Hoffman S; PathAI, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Elliott H; PathAI, Boston, MA, USA.; BigHat Biosciences, San Mateo, CA, USA., Leidal K; PathAI, Boston, MA, USA.; Genesis Therapeutics, Burlingame, CA, USA., Myers RP; Gilead Sciences, Inc., Foster City, CA, USA.; OrsoBio, Inc., Palo Alto, CA, USA., Chung C; Gilead Sciences, Inc., Foster City, CA, USA.; Inipharm, San Diego, CA, USA., Billin AN; Gilead Sciences, Inc., Foster City, CA, USA., Watkins TR; Gilead Sciences, Inc., Foster City, CA, USA., Patterson SD; Gilead Sciences, Inc., Foster City, CA, USA., Resnick M; PathAI, Boston, MA, USA.; Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA., Wack K; PathAI, Boston, MA, USA., Glickman J; PathAI, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Burt AD; NIHRB Medical Research Center, Newcastle University, Newcastle, UK., Loomba R; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, San Diego, CA, USA., Sanyal AJ; Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, VCU School of Medicine, Richmond, VA, USA., Glass B; PathAI, Boston, MA, USA., Montalto MC; PathAI, Boston, MA, USA.; Amgen, Thousand Oaks, CA, USA., Taylor-Weiner A; PathAI, Boston, MA, USA.; Absci, Vancouver, WA, USA., Wapinski I; PathAI, Boston, MA, USA.; Sanofi Pharmaceuticals, Cambridge, MA, USA., Beck AH; PathAI, Boston, MA, USA. andy.beck@pathai.com.

Publikováno v: Nature medicine [Nat Med] 2024 Oct; Vol. 30 (10), pp. 2914-2923. Date of Electronic Publication: 2024 Aug 07.

Human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation

Autor: Xie, Wei, Lama, Lodoe, Adura, Carolina, Tomita, Daisuke, Glickman, J. Fraser, Tuschl, Thomas, Patel, Dinshaw J.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 2019 Jun 01. 116(24), 11946-11955.

Externí odkaz: https://www.jstor.org/stable/26743505